8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2004 / Randomized, placebo-controlled, matched-pairs, double-blind trial
A 6-month randomized, double-blind, matched-pairs trial evaluated 10 mg/day of stabilized oral NADH versus placebo in 26 patients with probable Alzheimer's disease. After 6 months, patients taking NADH showed no evidence of progressive cognitive deterioration and achieved significantly higher total scores on the MDRS compared with placebo (p < 0.05). Subscale analysis showed significantly better performance with NADH in verbal fluency (p = 0.019) and visual-constructional ability (p = 0.038), with a trend in abstract verbal reasoning (p = 0.08). No differences were found between groups for attention, memory, or Clinical Dementia Rating scores.
Demarin V, Podobnik SS, Storga-Tomic D, et al. Drugs Exp Clin Res, 2004. PMID 15134388
2004 / Double-blind, placebo-controlled crossover trial
Following a one-week elimination diet, 277 3-year-old children completed a three-week double-blind crossover study receiving either a placebo mixture or an active drink with artificial colourings (20 mg daily) and sodium benzoate (45 mg daily). Significant reductions in hyperactive behaviour occurred during the withdrawal phase. Based on parental reports, hyperactive behaviour increased significantly more during the active period compared to placebo, regardless of baseline hyperactivity or atopy status. No significant differences were observed on objective clinic testing.
Bateman B, Warner JO, Hutchinson E, et al. Arch Dis Child, 2004. PMID 15155391
2004 / Randomized controlled trial
Participants in the Age-Related Eye Disease Study were randomly assigned to receive daily antioxidants (500 mg vitamin C, 400 IU vitamin E, 15 mg beta carotene), zinc and copper (80 mg zinc, 2 mg cupric oxide), both, or placebo. A cognitive battery was administered to 2,166 elderly individuals after a median of 6.9 years of treatment. Treatment groups did not differ on any of the six cognitive tests (p > 0.05 for all), showing neither benefit nor harm on cognition.
Yaffe K, Clemons TE, McBee WL, et al. Neurology, 2004. PMID 15534261
2004 / Randomized, controlled, double-blind crossover trial
Eight Parkinson's disease patients completed a randomized, double-blind crossover trial challenging them with single doses of 200/50 mg L-dopa/carbidopa (LD/CD) and 15 g and 30 g of Mucuna pruriens preparation at weekly intervals. Compared with standard LD/CD, the 30 g mucuna dose led to a significantly faster onset of effect (34.6 vs 68.5 min; p = 0.021) and a 21.9% (37 min) longer mean on-time (p = 0.021). Peak L-dopa plasma concentrations were 110% higher and the area under the curve was 165.3% larger (p = 0.012) with 30 g mucuna. No significant differences were observed in dyskinesias or tolerability.
Katzenschlager R, Evans A, Manson A, et al. J Neurol Neurosurg Psychiatry, 2004. PMID 15548480
2003 / Randomized controlled dose-response trial
Healthy adults were randomized to 8 h, 6 h, or 4 h time in bed per night for 14 consecutive days, or subjected to 3 nights of total sleep deprivation (0 h). Chronic sleep restriction to 4 h or 6 h per night led to significant cumulative, dose-dependent deficits in cognitive performance across all tasks, equivalent to up to 2 nights of total sleep deprivation. Subjective sleepiness ratings increased acutely but showed only small further increases, with subjects largely unaware of their escalating deficits. Across conditions, lapses in behavioral alertness were near-linearly related to cumulative wakefulness exceeding 15.84 h (s.e. 0.73 h).
Van Dongen HP, Maislin G, Mullington JM, et al. Sleep, 2003. PMID 12683469
2003 / Crossover feeding trial
Healthy young women were fed diets containing 0.8 or 20 mg/d of manganese for 8 weeks each in a crossover design, with fat provided as either cocoa butter or corn oil. When consuming the low-manganese diet compared with the high-manganese diet, subjects absorbed a significantly higher percentage of (54)Mn but had a significantly longer biological half-life of absorbed (54)Mn. Manganese intake did not affect neurological measures and only minimally affected psychological variables, suggesting efficient homeostatic maintenance across these intake levels.
Finley JW, Penland JG, Pettit RE, et al. J Nutr, 2003. PMID 12949376
2002 / Randomized controlled trial
Twenty children with autistic syndromes and urinary peptide abnormalities were split into a diet group or an untreated control group of 10 children each. After one year of follow-up, children consuming the gluten- and casein-free diet demonstrated significantly better development compared to the control group.
Knivsberg AM, Reichelt KL, Høien T, et al. Nutr Neurosci, 2002. PMID 12168688
2002 / Randomized controlled trial
In a randomized double-blind, placebo-controlled 14-day trial, 81 healthy young adults took either 3,000 mg daily of sustained-release ascorbic acid or a placebo. Participants with partners logged sexual activity in diaries and completed depression inventories. Ascorbic acid increased penile-vaginal intercourse frequency, particularly in women and couples living apart, while also lowering Beck Depression scores compared to placebo.
Brody S Biol Psychiatry, 2002. PMID 12208645
2002 / Randomized controlled trial
A randomized trial tested cognitive performance after an overnight fast in 21 boys aged 9 to 12 years receiving a confectionery snack or a noncalorie snack. Ingestion of the confectionery snack significantly improved vigilance attention performance, showing higher hit rates and lower miss rates. False alarm rates declined with the confectionery snack over time. However, no significant differences appeared in tests of verbal memory, spatial memory, visual perception, or digit span.
Busch CR, Taylor HA, Kanarek RB, et al. Physiol Behav, 2002. PMID 12419410
2002 / Laboratory experiment (2x2x2 factorial design)
An experiment with a 2 (restrained/unrestrained) x 2 (distraction yes/no) x 2 (perceived calories high/low) design evaluated ice-cream consumption in a taste test setting. A significant interaction was found: in the high-calorie condition, restrained eaters ate the same amount as unrestrained eaters when not distracted, but considerably more when distracted. Additionally, an unexpected main effect showed that both restrained and unrestrained eaters consumed more ice cream when distracted than when not distracted.
Boon B, Stroebe W, Schut H, et al. Br J Health Psychol, 2002. PMID 14596713
2001 / Randomized controlled trial
A double-blind randomized trial assigned 239 term infants to receive formula with or without arachidonic acid and docosahexaenoic acid for 1 year, alongside 165 breastfed reference infants. While supplemented formulas increased plasma and red blood cell fatty acid levels to match breastfed infants, no developmental test results differed among groups from birth to 14 months. Measures of growth, visual acuity, information processing, language, and temperament showed no benefits.
Auestad N, Halter R, Hall RT, et al. Pediatrics, 2001. PMID 11483802
2001 / Three randomized controlled trials
Across three studies involving 36 volunteers, consumption of Red Bull Energy Drink was evaluated against control beverages. The energy drink improved cycle ergometer aerobic endurance (maintaining 65-75% maximum heart rate) and anaerobic output at maximum speed (P < 0.05). Participants also demonstrated better choice reaction times, concentration via number cancellation, immediate recall memory, and higher subjective alertness.
Alford C, Cox H, Wescott R Amino Acids, 2001. PMID 11665810
2000 / Intervention trial (three conditions)
Nine healthy female volunteers were evaluated under three sleep conditions in winter: sleep after bathing, sleep after a hot footbath, and sleep without either treatment. Rectal temperature increased by approximately 1.0 degree C after bathing but not after the footbath compared to control, while mean skin temperature increased in both treatment conditions. Sleep onset latency was shortened and body movements during the first 30 minutes of sleep were reduced under both treatment conditions compared with control. REM sleep decreased with bathing compared to footbath, stage 3 sleep was greater after footbath compared to control, and subjective sleep sensations were better following both treatments.
Sung EJ, Tochihara Y J Physiol Anthropol Appl Human Sci, 2000. PMID 10979246
2000 / 3-month open-label study
Researchers conducted a 3-month open-label study administering 10 mg/day of oral reduced nicotinamide adenine dinucleotide (NADH) to 25 patients with mild to moderate dementia alongside their current cholinomimetic medication. Among the 19 patients who completed the study, no evidence was found for any cognitive effect assessed by established psychometric tests. The authors concluded that NADH is unlikely to produce cognitive improvements of the magnitude reported earlier.
Rainer M, Kraxberger E, Haushofer M, et al. J Neural Transm (Vienna), 2000. PMID 11459000
1999 / Controlled trial
Researchers measured salivary free cortisol in healthy men before and after high-protein midday meals (39% energy as protein) compared with a fasting day, and in healthy women consuming high-protein (32%) or low-protein (5%) meals. An acute increase in cortisol occurred following high-protein meals but not after the low-protein meal. The magnitude of this cortisol increase in women correlated significantly with poorer psychological well-being.
Gibson EL, Checkley S, Papadopoulos A, et al. Psychosom Med, 1999. PMID 10204975
1999 / Randomized controlled trial
A 16-week randomized controlled trial evaluated 156 adults aged 50 years or older with major depressive disorder assigned to aerobic exercise, sertraline hydrochloride, or combination therapy. After 16 weeks, depression scores on HAM-D and BDI did not differ statistically among groups (P = .67), and all arms showed significant reductions. Medication produced the fastest initial response, while combination therapy showed quicker early improvement among participants who started with less severe symptoms.
Blumenthal JA, Babyak MA, Moore KA, et al. Arch Intern Med, 1999. PMID 10547175
1999 / Intervention trial (pre-post)
A 12-week study evaluated the impact of limiting dietary fat to no more than 20 g/day in 54 migraine patients following a 28-day baseline and a 28-day run-in period. Participants significantly decreased dietary fat intake from baseline (mean 65.9 g/day) to the final 28-day postintervention period (mean 27.8 g/day, p < 0.0001). The reduction in dietary fat was associated with statistically significant decreases in headache frequency, intensity, duration, and medication intake (all p < 0.0001). A significant positive correlation was also observed between baseline fat intake and headache frequency (r = .44, p = 0.02).
Bic Z, Blix GG, Hopp HP, et al. J Womens Health Gend Based Med, 1999. PMID 10839648
1998 / Double-masked randomized clinical trial
A double-masked trial evaluated term infant formula supplemented with DHA (0.35%) or DHA (0.36%) and AA (0.72%) compared to unsupplemented formula and a breast-fed reference group. Supplementation during the first 4 months produced differences in total red blood cell (RBC) lipid composition and led to better sweep VEP acuity at 6, 17, and 52 weeks of age, but not at 26 weeks. Supplemented infants showed RBC lipid composition and sweep VEP acuity similar to breast-fed infants, whereas unsupplemented infants differed significantly from breast-fed infants. Differences in acuity were not detected by forced choice preferential looking, and infants in all diet groups demonstrated similar growth rates and tolerance.
Birch EE, Hoffman DR, Uauy R, et al. Pediatr Res, 1998. PMID 9702915
1997 / Double-blind, placebo-controlled, randomized multicenter trial
A 2-year randomized trial assigned 341 patients with moderate Alzheimer's disease to receive selegiline (10 mg/day), alpha-tocopherol (vitamin E, 2000 IU/day), both, or placebo. In unadjusted analyses, there was no statistically significant difference in outcomes among the four groups. After adjusting for baseline Mini-Mental State Examination scores, significant delays in time to the primary outcome were observed for selegiline (median 655 days, P=0.012), alpha-tocopherol (median 670 days, P=0.001), and combination therapy (median 585 days, P=0.049) compared with placebo (median 440 days).
Sano M, Ernesto C, Thomas RG, et al. N Engl J Med, 1997. PMID 9110909
1996 / Open-label pilot trial
An open-label trial evaluated nicotinamide adenine dinucleotide (NADH) medication in 17 patients with dementia of the Alzheimer type for 8 to 12 weeks. All evaluated patients showed improvement in cognitive dysfunction, with Mini-Mental State Examination scores improving by a mean of 8.35 points (range: 6 to 14 points) and Global Deterioration Scale scores improving by a mean of 1.82 (range: 1 to 2 points). No side effects or adverse effects were reported during observation periods exceeding a year in some patients. The authors noted that this pilot study does not allow definitive conclusions and that a double-blind placebo-controlled study is necessary.
Birkmayer JG Ann Clin Lab Sci, 1996. PMID 8834355
1996 / Multicenter, randomized, double-blind, placebo-controlled trial
In an interim evaluation of 69 patients with 2 to 6 migraine attacks per month, 10 of 35 patients (28.6%) taking 10 mmol magnesium twice daily responded, compared to 10 of 34 (29.4%) taking placebo. Migraine days and attacks showed no difference between groups. Mild adverse events occurred in 45.7% of the magnesium group versus 23.5% with placebo, prompting trial discontinuation.
Pfaffenrath V, Wessely P, Meyer C, et al. Cephalalgia, 1996. PMID 8902254
1996 / Controlled clinical trial
Ten healthy middle-aged men were given a moderate dose of ethanol (0.55 g/kg of body weight) 6 hours before scheduled bedtime and compared to a mineral water control condition. Breath-ethanol concentrations reached zero in all subjects by bedtime. Sleep was perceived as more superficial, while sleep efficiency, total sleep time, stage 1, and REM sleep were reduced, and wakefulness doubled in the second half of the night. EEG power density was enhanced in low delta frequencies during non-REM (1.25-2.5 Hz) and REM sleep (1.25-1.5 Hz), and slow wave sleep showed power density increases in low-frequency, alpha (8.25-9.0 Hz), and sigma (12.25-13.0 Hz) bands.
Landolt HP, Roth C, Dijk DJ, et al. J Clin Psychopharmacol, 1996. PMID 8959467
1995 / Placebo-controlled trial
Nine healthy men were administered 200 mg of caffeine or placebo at 07.10 h to evaluate sleep stages and EEG power spectra during the subsequent night. Salivary caffeine levels decreased from a peak of 17 mumol/l at one hour post-intake to 3 mumol/l prior to sleep at 23.00 h. Compared to placebo, morning caffeine intake significantly reduced sleep efficiency and total sleep time. In nonREM sleep, EEG power density was suppressed in the 0.25-0.5 Hz band and enhanced in sleep spindle ranges (11.25-12.0 Hz and 13.25-14.0 Hz), while in REM sleep, EEG power density was suppressed in the 0.75-4.5 and 5.25-6.0 Hz bands.
Landolt HP, Werth E, Borbély AA, et al. Brain Res, 1995. PMID 7796154
1995 / Intervention trial with healthy control group
Researchers evaluated the efficacy of an elimination diet (free of cow's milk or other skin-test-positive foods) in 36 autistic patients over 8 weeks, while comparing food antibody levels to 20 healthy children. Patients showed a marked improvement in behavioral symptoms after 8 weeks on the elimination diet. Autistic patients also had significantly higher levels of IgA antibodies to casein, lactalbumin, and beta-lactoglobulin, as well as IgG and IgM to casein, compared with the 20 healthy controls.
Lucarelli S, Frediani T, Zingoni AM, et al. Panminerva Med, 1995. PMID 8869369